애로우헤드 파마슈티컬스(ARWR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $67.13 (-0.90%), 시가총액 $10.64B, 52주 최저~최고 $14.71 ~ $79.69.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clin
애로우헤드 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
애로우헤드 파마슈티컬스의 현재 주가는 $67.13 (-0.90%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
애로우헤드 파마슈티컬스의 시가총액은 약 $10.64B입니다.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phas